| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B2MG; Beta 2 microglobin; Beta 2 microglobulin; Beta-2-microglobulin form pI 5.3; CDABP0092; Hdcma22p |
| Entrez GeneID | 567 |
| WB Predicted band size | Calculated MW: 14 kDa; Observed MW: 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Recombinant protein of human beta 2 Microglobulin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3条关于β2微球蛋白(β2M)抗体的参考文献示例：
1. **"Development of a high-sensitivity ELISA for beta-2 microglobulin in serum"**
- **作者**: Smith J, et al.
- **摘要**: 本研究开发了一种新型ELISA检测方法，用于高灵敏度测量血清中的β2M水平，验证了其在慢性肾脏病(CKD)患者中的诊断准确性，并证实其优于传统检测技术。
2. **"Beta-2 microglobulin amyloidosis: Role of monoclonal antibodies in targeting pathological aggregates"**
- **作者**: Chen L, et al.
- **摘要**: 文章探讨了β2M在透析相关淀粉样变性中的沉积机制，并评估了特异性单克隆抗体在体外和小鼠模型中溶解淀粉样纤维的潜在治疗作用。
3. **"Beta-2 microglobulin as a biomarker in multiple myeloma: implications for CAR-T cell therapy"**
- **作者**: Rodriguez M, et al.
- **摘要**: 研究分析了β2M在多发性骨髓瘤患者中的表达水平与预后的关联，并探索了基于抗β2M抗体的CAR-T细胞疗法在临床前实验中的抗肿瘤效果。
(注：以上文献为示例，实际引用需根据具体研究查阅真实数据库如PubMed、ScienceDirect等。)
Beta-2 microglobulin (B2M) is a 12 kDa protein component of the major histocompatibility complex (MHC) class I molecule, expressed on nearly all nucleated cells. It plays a critical role in immune surveillance by stabilizing MHC-I structure and presenting antigenic peptides to CD8+ T cells. B2M is constitutively shed into biological fluids, with serum and urine levels serving as biomarkers for renal dysfunction, inflammatory diseases, and certain cancers. Elevated B2M correlates with conditions like multiple myeloma, chronic kidney disease, and autoimmune disorders.
Antibodies targeting B2M are essential tools in research and diagnostics. Monoclonal and polyclonal anti-B2M antibodies are widely used in immunoassays (e.g., ELISA, Western blot), immunohistochemistry, and flow cytometry to quantify B2M expression, assess MHC-I surface localization, or study disease mechanisms. In clinical settings, they aid in monitoring B2M levels for disease progression or treatment response. Therapeutic applications are also explored, including blocking B2M to modulate immune responses in transplantation or cancer immunotherapy. However, challenges remain, such as ensuring antibody specificity given B2M’s structural similarity to other immunoglobulin domains. Recent advances include recombinant antibodies engineered for enhanced affinity, supporting precision in both basic research and translational studies.
×
